Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Karyopharm and Medidata Expand Clinical Trial Partnership

By Medidata | April 5, 2017

Medidata and clinical-stage pharmaceutical company Karyopharm Therapeutics announced an expanded partnership to bring novel machine-learning technology and targeted risk-based monitoring (RBM) techniques to clinical oncology trials.

In addition to renewing its use of the Medidata Clinical Cloud platform—including key capabilities within Medidata’s study conduct and site support suites—Karyopharm is adopting Medidata CSA (Centralized Statistical Analytics) and Medidata TSDV (Targeted Source Document Verification) to enhance its data review process and incorporate modern risk assessment practices into its drug development programs.

“As we advance our most promising cancer therapies, it is vital that Karyopharm embraces the latest technologies and evolving trends in the clinical trials space. Adopting Medidata’s machine-learning capabilities for centralized monitoring will not only put us in line with the updated ICH E6 R2 guidelines, but will also allow us to view clinical information at a more holistic level, better prioritize trial resources, and maintain data quality and integrity,” said Ran Frenkel, chief development operations officer at Karyopharm. “Medidata is more than our technology provider of choice—they are a valued partner that is helping us reach our scientific goals sooner.”

A Medidata customer since 2014, Karyopharm has been using Medidata’s electronic data capture (EDC) and management system, Medidata Rave, as well as integrated capabilities that plug into Rave—including randomization and trial supply management, medical coding, adverse event reporting and clinical trial management—to advance its pipeline of oncology-focused therapies. Together, these unified applications have streamlined Karyopharm’s clinical trial processes: reducing electronic case report form (eCRF) design times by 74 percent, improving data entry time by 64 percent, and reducing the cycle time to open, answer and close queries by 41 percent.

Now, Karyopharm will realize more value from the Medidata platform by leveraging Medidata CSA and Medidata TSDV, two integral capabilities within Medidata’s Strategic Monitoring solution.

CSA’s machine-learning capabilities help to identify unusual clinical trial data anomalies within a study, enabling better prioritization of resources around data quality and integrity, as well as patient safety. Medidata CSA simplifies the site monitoring process, making it easier for teams to detect and track critical data errors throughout a clinical trial, while Medidata TSDV optimizes the data verification process by enabling sponsors to configure study-specific and site-specific SDV plans.

(Source: Business Wire)


Filed Under: Drug Discovery

 

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE